Cell & Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis By Type, By Indication, By Application, By End-user, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Global Cell & Gene Therapy Manufacturing Services Market projected to be worth USD 20.68 billion by 2030.
According to SPER Market Research, the Cell & Gene Therapy Manufacturing Services Market estimated to reach USD 20.68 billion by 2030 with a CAGR of 11.6%. The collaboration between pharmaceutical companies and CDMOs, rising prevalence of cancer and various targeted disease, rising pharmaceutical research & development, High investments by CDMOs in advanced technology; these factors act as the fuel to the escalation of the market.
Impact of COVID-19 on the Cell & Gene Therapy Manufacturing Services Market
Because of the outbreak of COVID-19, there is disruption of clinical trials due to the deferral of patient enrolment. Clinical trials such as; cardiovascular disease, respiratory disease, oncology, anti-infective, were the worst-hit in this time. This leads to the squeeze of production and research.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered ABL Inc., Andelyn Biosciences, Anemocyte Srl, BioCentriq, Catalent, Inc., Cell and Gene Therapy Catapult, Charles River Laboratories, Commercializing Living Therapies, ElevateBio, F. Hoffmann-La Roche Ltd., FinVector, FUJIFILM Holdings Corporation, JRS PHARMA, Lonza, Merck KGaA, NIKON CORPORATION, Oxford Biomedica plc, Porton Biopharma Limited, Resilience, RoslinCT, Takara Bio Inc., The Discovery Labs LLC, Thermo Fisher Scientific, Inc., Vibalogics, WuXi AppTec
Driver: rising investments in pharmaceutical Research & Development
The key drivers to the escalation of the market are; towering prevalence of cancer and other target diseases, rising investments in pharmaceutical research & development, funding in advanced technologies by CDMOs, escalating partnerships and agreements among CDMOs and pharmaceutical companies.
Restraint: High running costs coupled with cell & gene therapy manufacturing
The manufacturing of cell & gene therapy is costly; this might resist the expansion of market.
Opportunity: growing figure of cell & gene therapy clinical trials
The demand for cell & gene therapies is escalating globally, the elevated number of cell & gene therapy clinical trials; give the impetus to the top player in this market.
Challenges:
There is chances of superfluous outcomes and threat of mutagenesis; are the challenges to this market.
Global Cell & Gene Therapy Manufacturing Services Market, By Type:
Based on the Type, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cell Therapy {Allogeneic (Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, Other Allogeneic Cells, T-cells), Autologous (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, T-cells), Viral Vector (Adeno-associated Virus Vectors, Other Viral Vectors, Retroviral Vectors)}, Gene Therapy {Non-viral Vector, Oligonucleotides, Viral Vector (Retroviral Vectors, Adeno-associated Virus Vectors, Other Viral Vectors)}.
Global Cell & Gene Therapy Manufacturing Services Market, By Indication:
Based on the Indication, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, Orthopaedic Diseases, Other Indications
Global Cell & Gene Therapy Manufacturing Services Market, By Application:
Based on the Application, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Clinical Manufacturing, Commercial Manufacturing.
Global Cell & Gene Therapy Manufacturing Services Market, By End User:
Based on the End-Users, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Other End Users.
Global Cell & Gene Therapy Manufacturing Services Market, By Region:
North America owns the prime share of this market; this is due to the increasing prevalence of cancer, increasing research in stem cell and cancer in this region.
According to SPER Market Research, the Cell & Gene Therapy Manufacturing Services Market estimated to reach USD 20.68 billion by 2030 with a CAGR of 11.6%. The collaboration between pharmaceutical companies and CDMOs, rising prevalence of cancer and various targeted disease, rising pharmaceutical research & development, High investments by CDMOs in advanced technology; these factors act as the fuel to the escalation of the market.
Impact of COVID-19 on the Cell & Gene Therapy Manufacturing Services Market
Because of the outbreak of COVID-19, there is disruption of clinical trials due to the deferral of patient enrolment. Clinical trials such as; cardiovascular disease, respiratory disease, oncology, anti-infective, were the worst-hit in this time. This leads to the squeeze of production and research.
Scope of the report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered ABL Inc., Andelyn Biosciences, Anemocyte Srl, BioCentriq, Catalent, Inc., Cell and Gene Therapy Catapult, Charles River Laboratories, Commercializing Living Therapies, ElevateBio, F. Hoffmann-La Roche Ltd., FinVector, FUJIFILM Holdings Corporation, JRS PHARMA, Lonza, Merck KGaA, NIKON CORPORATION, Oxford Biomedica plc, Porton Biopharma Limited, Resilience, RoslinCT, Takara Bio Inc., The Discovery Labs LLC, Thermo Fisher Scientific, Inc., Vibalogics, WuXi AppTec
Driver: rising investments in pharmaceutical Research & Development
The key drivers to the escalation of the market are; towering prevalence of cancer and other target diseases, rising investments in pharmaceutical research & development, funding in advanced technologies by CDMOs, escalating partnerships and agreements among CDMOs and pharmaceutical companies.
Restraint: High running costs coupled with cell & gene therapy manufacturing
The manufacturing of cell & gene therapy is costly; this might resist the expansion of market.
Opportunity: growing figure of cell & gene therapy clinical trials
The demand for cell & gene therapies is escalating globally, the elevated number of cell & gene therapy clinical trials; give the impetus to the top player in this market.
Challenges:
There is chances of superfluous outcomes and threat of mutagenesis; are the challenges to this market.
Global Cell & Gene Therapy Manufacturing Services Market, By Type:
Based on the Type, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cell Therapy {Allogeneic (Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, Other Allogeneic Cells, T-cells), Autologous (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, T-cells), Viral Vector (Adeno-associated Virus Vectors, Other Viral Vectors, Retroviral Vectors)}, Gene Therapy {Non-viral Vector, Oligonucleotides, Viral Vector (Retroviral Vectors, Adeno-associated Virus Vectors, Other Viral Vectors)}.
Global Cell & Gene Therapy Manufacturing Services Market, By Indication:
Based on the Indication, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, Orthopaedic Diseases, Other Indications
Global Cell & Gene Therapy Manufacturing Services Market, By Application:
Based on the Application, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Clinical Manufacturing, Commercial Manufacturing.
Global Cell & Gene Therapy Manufacturing Services Market, By End User:
Based on the End-Users, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Other End Users.
Global Cell & Gene Therapy Manufacturing Services Market, By Region:
North America owns the prime share of this market; this is due to the increasing prevalence of cancer, increasing research in stem cell and cancer in this region.
1. INTRODUCTION
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Cell & Gene Therapy Manufacturing Services Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019-2030 (USD MILLION)
6.1. Cell Therapy
6.1.1. Allogeneic
6.1.1.1. Hematopoietic Stem Cells
6.1.1.2. Induced Pluripotent Stem Cells
6.1.1.3. Mesenchymal Stem Cells
6.1.1.4. Natural Killer Cells
6.1.1.5. Other Allogeneic Cells
6.1.1.6. T-cells
6.1.2. Autologous
6.1.2.1. Hematopoietic Stem Cells
6.1.2.2. Mesenchymal Stem Cells
6.1.2.3. Natural Killer Cells
6.1.2.4. T-cells
6.1.3. Viral Vector
6.1.3.1. Adeno-associated Virus Vectors
6.1.3.2. Other Viral Vectors
6.1.3.3. Retroviral Vectors
6.2. Gene Therapy
6.2.1. Non-viral Vector
6.2.2. Oligonucleotides
6.2.2.1. Other Non-viral Vectors
6.2.3. Viral Vector
6.2.3.1. Retroviral Vectors
6.2.3.2. Adeno-associated Virus Vectors
6.2.3.3. Other Viral Vectors
7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019-2030 (USD MILLION)
7.1. Cardiovascular Diseases
7.2. Central Nervous System Disorders
7.3. Infectious Diseases
7.4. Oncology Diseases
7.5. Ophthalmology Diseases
7.6. Orthopedic Diseases
7.7. Other Indications
8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019-2030 (USD MILLION)
8.1. Clinical Manufacturing
8.2. Commercial Manufacturing
9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION)
9.1. Academic & Research Institutes
9.2. Other End Users
9.3. Pharmaceutical & Biotechnology Companies
10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019-2030 (USD MILLION)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. Europe
10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. COMPANY PROFILES
11.1. ABL, Inc.
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Andelyn Biosciences
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Anemocyte Srl
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. BioCentriq
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Catalent, Inc.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Cell and Gene Therapy Catapult
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Charles River Laboratories
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Commercializing Living Therapies
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. ElevateBio
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. F. Hoffmann-La Roche Ltd.
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. FinVector
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. FUJIFILM Holdings Corporation
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. JRS PHARMA
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.14. Lonza
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. Merck KGaA
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. NIKON CORPORATION
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. Oxford Biomedica plc
11.17.1 Company details
11.17.2 Financial outlook
11.17.3 Product summary
11.17.4 Recent developments
11.18. Porton Biopharma Limited
11.18.1. Company details
11.18.2. Financial outlook
11.18.3. Product summary
11.18.4. Recent developments
11.19. Resilience
11.19.1. Company details
11.19.2. Financial outlook
11.19.3. Product summary
11.19.4. Recent developments
11.20. RoslinCT
11.20.1. Company details
11.20.2. Financial outlook
11.20.3. Product summary
11.20.4. Recent developments
11.21. Takara Bio Inc.
11.21.1. Company details
11.21.2. Financial outlook
11.21.3. Product summary
11.21.4. Recent developments
11.22. The Discovery Labs LLC
11.22.1. Company details
11.22.2. Financial outlook
11.22.3. Product summary
11.22.4. Recent developments
11.23. Thermo Fisher Scientific, Inc.
11.23.1. Company details
11.23.2. Financial outlook
11.23.3. Product summary
11.23.4. Recent developments
11.24. Vibalogics
11.24.1. Company details
11.24.2. Financial outlook
11.24.3. Product summary
11.24.4. Recent developments
11.25. WuXi AppTec
11.25.1 Company details
11.25.2 Financial outlook
11.25.3 Product summary
11.25.4 Recent developments
1.1. Scope of the report
1.2. Market segment analysis
2. RESEARCH METHODOLOGY
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Cell & Gene Therapy Manufacturing Services Market
5. MARKET VARIABLES AND OUTLOOK
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019-2030 (USD MILLION)
6.1. Cell Therapy
6.1.1. Allogeneic
6.1.1.1. Hematopoietic Stem Cells
6.1.1.2. Induced Pluripotent Stem Cells
6.1.1.3. Mesenchymal Stem Cells
6.1.1.4. Natural Killer Cells
6.1.1.5. Other Allogeneic Cells
6.1.1.6. T-cells
6.1.2. Autologous
6.1.2.1. Hematopoietic Stem Cells
6.1.2.2. Mesenchymal Stem Cells
6.1.2.3. Natural Killer Cells
6.1.2.4. T-cells
6.1.3. Viral Vector
6.1.3.1. Adeno-associated Virus Vectors
6.1.3.2. Other Viral Vectors
6.1.3.3. Retroviral Vectors
6.2. Gene Therapy
6.2.1. Non-viral Vector
6.2.2. Oligonucleotides
6.2.2.1. Other Non-viral Vectors
6.2.3. Viral Vector
6.2.3.1. Retroviral Vectors
6.2.3.2. Adeno-associated Virus Vectors
6.2.3.3. Other Viral Vectors
7. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019-2030 (USD MILLION)
7.1. Cardiovascular Diseases
7.2. Central Nervous System Disorders
7.3. Infectious Diseases
7.4. Oncology Diseases
7.5. Ophthalmology Diseases
7.6. Orthopedic Diseases
7.7. Other Indications
8. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019-2030 (USD MILLION)
8.1. Clinical Manufacturing
8.2. Commercial Manufacturing
9. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019-2030 (USD MILLION)
9.1. Academic & Research Institutes
9.2. Other End Users
9.3. Pharmaceutical & Biotechnology Companies
10. GLOBAL CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019-2030 (USD MILLION)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. Europe
10.2.1. Germany
10.2.2. United Kingdom
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Australia
10.3.5. South Korea
10.3.6. Rest of Asia-Pacific
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. COMPANY PROFILES
11.1. ABL, Inc.
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Andelyn Biosciences
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Anemocyte Srl
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. BioCentriq
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Catalent, Inc.
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Cell and Gene Therapy Catapult
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Charles River Laboratories
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. Commercializing Living Therapies
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. ElevateBio
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. F. Hoffmann-La Roche Ltd.
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. FinVector
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. FUJIFILM Holdings Corporation
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. JRS PHARMA
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.14. Lonza
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. Merck KGaA
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. NIKON CORPORATION
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. Oxford Biomedica plc
11.17.1 Company details
11.17.2 Financial outlook
11.17.3 Product summary
11.17.4 Recent developments
11.18. Porton Biopharma Limited
11.18.1. Company details
11.18.2. Financial outlook
11.18.3. Product summary
11.18.4. Recent developments
11.19. Resilience
11.19.1. Company details
11.19.2. Financial outlook
11.19.3. Product summary
11.19.4. Recent developments
11.20. RoslinCT
11.20.1. Company details
11.20.2. Financial outlook
11.20.3. Product summary
11.20.4. Recent developments
11.21. Takara Bio Inc.
11.21.1. Company details
11.21.2. Financial outlook
11.21.3. Product summary
11.21.4. Recent developments
11.22. The Discovery Labs LLC
11.22.1. Company details
11.22.2. Financial outlook
11.22.3. Product summary
11.22.4. Recent developments
11.23. Thermo Fisher Scientific, Inc.
11.23.1. Company details
11.23.2. Financial outlook
11.23.3. Product summary
11.23.4. Recent developments
11.24. Vibalogics
11.24.1. Company details
11.24.2. Financial outlook
11.24.3. Product summary
11.24.4. Recent developments
11.25. WuXi AppTec
11.25.1 Company details
11.25.2 Financial outlook
11.25.3 Product summary
11.25.4 Recent developments
